Early patterns of adherence in adolescents initiating highly active antiretroviral therapy predict long-term adherence, virologic, and immunologic control.
Early patterns of adherence in adolescents initiating highly active antiretroviral therapy predict long-term adherence, virologic, and immunologic control.
复制标题
开始高效抗逆转录病毒治疗的青少年的早期依从模式可预测长期依从性、病毒学和免疫学控制。
DOI：
10.1089/apc.2009.0081
复制
发表时间：
2009
影响因子：
4.9
通讯作者：
Flynn,PatriciaM
中科院分区：
文献类型：
--
作者：
Lindsey,JaneC;Bosch,RonaldJ;Rudy,BretJ;Flynn,PatriciaM
亲爱的编辑：高活性抗逆转录病毒治疗（HAART）是有效的降低病毒载量在成人和儿童，如果服用处方。目前尚不清楚患者错过剂量的频率或持续时间，或者对不同效力或给药频率的不同治疗方案的不充分坚持模式如何影响病毒学控制和免疫状态。1,2对于如何最好地衡量患者对治疗的依从性也缺乏明确的认识。青少年占新感染艾滋病毒的大多数3，他们往往难以坚持新的药物治疗方案。先前已经证明，在4 - 16周开始HAART的青少年自我报告的“完美”依从性较好，短期（24周）和长期（144周）病毒学控制较好。完全依从性被定义为在四次研究访问前3天内报告没有遗漏抗逆转录病毒剂量的青少年。这项措施是限制性的，因为它不能区分青少年在一次研究访问中可能只错过了一次剂量，一次访问中可能错过了所有剂量，或者在所有研究访问中可能错过了所有剂量。本报告的目的是评估早期自我报告依从性的其他措施在预测长期病毒学、免疫学和依从性结果方面的能力。儿童艾滋病临床试验组（PACTG） 381方案是一项观察性研究，对120名11-22岁的青少年通过危险行为感染艾滋病毒，开始HAART治疗，随访长达3年。该研究于1999年3月开始接受登记，并于2004年11月结束随访。该研究得到了各机构审查委员会的批准，并获得了所有参与者的知情同意。
Dear Editor: Highly active antiretroviral therapy (HAART) is effective in lowering viral load in adults and children when taken as prescribed. It is less clear how often or for how long patients can miss doses, or how patterns of inadequate adherence to different treatment regimens with different potency or dosing frequency influence virologic control and immune status. 1, 2 There is also lack of clarity in how best to measure patient adherence to treatment. Adolescents, who account for the majority of new HIV infections, 3 often have difficulty adhering to new medication regimens. 4, 5 It has previously been demonstrated that adolescents starting HAART with ‘‘perfect’’self-reported adherence at weeks 4–16 had better short (24 week) and long-term (144 week) virologic control. 6 Perfect adherence was defined as the adolescent reporting no antiretroviral doses missed in the 3 days prior to each of four study visits. This measure was restrictive as it could not distinguish between adolescents who might only have missed one dose at one study visit, all doses at one visit, or all doses at all study visits. The goal in this report was to assess other measures of early self-reported adherence in their ability to predict long-term virologic, immunologic, and adherence outcomes.Pediatric AIDS Clinical Trials Group (PACTG) Protocol 381 was an observational study of 120 adolescents 11–22 years of age infected with HIV through risk behaviors, initiating HAART and followed for up to 3 years. 6 The study opened to enrollment in March 1999 and closed to follow-up in November 2004. The study was approved by the Institutional Review Board at each site and informed consent obtained from all participants.
影响因子：
7.6
作者：
D'Angelo, LJ;Samples, C;Friedman, L
通讯作者：
Friedman, L